The eradication of Jurkat-Ras tumors with cc49scFv-FasLext without hepatic toxicity warrants the screening of human hematopoietic cancer repositories for TAG-72 and Fas expression and their subsequent curability with this reagent. This evidence concerns the gene FAS and hematopoietic and lymphoid cell neoplasm.